A5100734327- Retinoids in leukemia and cellular processes
- Acute Myeloid Leukemia Research
- Antioxidant Activity and Oxidative Stress
- Arsenic contamination and mitigation
- Drug-Induced Ocular Toxicity
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Acne and Rosacea Treatments and Effects
- Advanced biosensing and bioanalysis techniques
- Immune Response and Inflammation
- Inflammation biomarkers and pathways
- Bone and Joint Diseases
- Blood Coagulation and Thrombosis Mechanisms
- Estrogen and related hormone effects
- Immune cells in cancer
- Chemokine receptors and signaling
- interferon and immune responses
- Inflammatory Biomarkers in Disease Prognosis
- Peroxisome Proliferator-Activated Receptors
- Ion channel regulation and function
- Extracellular vesicles in disease
- Zebrafish Biomedical Research Applications
- Eicosanoids and Hypertension Pharmacology
- Synthesis and biological activity
- Cytokine Signaling Pathways and Interactions
- Retinal Diseases and Treatments
Harbin Medical University
2011-2021
First Affiliated Hospital of Harbin Medical University
2008-2021
Southern University of Science and Technology
2021
Brigham and Women's Hospital
2016
Harvard University
2016
VA Boston Healthcare System
2016
Nanjing University of Chinese Medicine
2015
Heilongjiang Institute of Wood Science
2014
Shangri-la Institute
2004
University of Alberta
2003
Arsenic has been used successfully in clinical trials for treating acute promyelocytic leukemia (APL). Although sublethal doses of inorganic arsenic are used, little is known about the pharmacokinetics and metabolism high levels APL patients. To fill this important gap, study describes speciation urine from four patients treated with arsenic. Each patient was injected daily an arsenite (AsIII) solution that contained 10 mg As2O3 precursor. Speciation analysis samples collected consecutively...
The prognosis of acute promyelocytic leukemia (APL) in the elderly is poorer than that younger patients after treatment with all-trans retinoic acid plus chemotherapy, which current standard therapy for APL. A significantly higher mortality during consolidation was found, mainly due to deaths from sepsis following chemotherapy-induced myelosuppression.A total 33 aged 60 years or older de novo APL were treated single-agent arsenic trioxide (ATO) remission induction and postremission therapy....
Arsenic trioxide has been successfully used as a therapeutic in the treatment of acute promyelocytic leukemia (APL). Detailed monitoring arsenic and its metabolites various accessible specimens APL patients can contribute to improving efficacy minimizing arsenic-induced side effects. This article focuses on determination species saliva samples from undergoing treatment. Saliva were collected nine over three consecutive days. The received 10 mg each day via intravenous infusion. analyzed...
Objectives: Catastrophic hemorrhage remains the main cause of acute promyelocytic leukemia (APL) treatment failure. This study was aimed to pathogenesis coagulopathy in patients with APL.Methods: Multiple procoagulant and profibrinolytic parameters plasma peripheral leukocytes from 24 newly diagnosed APL accompanied by before after arsenic trioxide (ATO) were evaluated.Results: Prior treatment, had elevated D-dimer decreased fibrinogen levels. Plasma urokinase-type plasminogen activator...
We evaluated cellular origin, numbers, and procoagulant activity of phosphatidylserine-positive microparticles (MPs) among subgroups in acute coronary syndromes (ACS).Parameters were measured on admission, days 1 (within 24 h admission), 2, 3, 7. All ST-elevated myocardial infarction (STEMI) patients presented more than 3 from symptom onset received fibrinolysis treatment; controls included unstable angina non-STEMI as well healthy controls. Phosphatidylserine-positive MPs detected by flow...
Although arsenic has shown remarkable therapeutic efficacy in patients with acute promyelocytic leukemia (APL), its side effects are rarely reported. In this article, the associations among urinary profiles, hematological and biochemical values, 3 AS3MT genotypes (rs3740392, rs3740390, rs11191439) were evaluated 50 APL treated trioxide (As2O3). Results revealed levels of serum enzymes (ALT, AST, GGT), GLU count WBC NEUT#, which markers hepatic damage, diabetes leukocytosis, respectively,...
Objective: Many patients with psoriasis have developed acute promyelocytic leukemia (APL) whereas few reports on psoriasis-associated APL were found in the published literature. This study was aimed to etiology, clinical characteristics, and prognosis of map a suitable treatment regime for this condition.Methods: retrospectively analyzed data 17 diagnosed treated our hospital past decade.Results: The accounted 8.3% total de novo during same period hospital. Their characteristics similar...
BackgroundThe role of vascular endothelium in acute promyelocytic leukaemia (APL) remains unknown. We aimed to investigate the mechanisms by which APL cells interact with endothelial (ECs) and further explore how affects bleeding as well therapeutic interventions.MethodAPL an original cell line, NB4 cells, were used for experiments. The effects leukaemic on ECs analyzed vitro vivo. Moreover, barrier function procoagulant activity detected. An mouse model was established vivo...
Background: Arsenic trioxide (ATO) is successfully applied to treat acute promyelocytic leukemia (APL). species levels in blood are critical reveal metabolic mechanism and relationship between arsenic clinical response. Characteristics influence factors of APL patients have not been studied.Methods: 305 plasma samples from treated with ATO were analyzed using HPLC-HG-AFS. Trough concentration (Ctrough), distribution, methylation evaluated. The on association concentrations efficacy...
Background: Early death (ED) rate in acute promyelocytic leukemia (APL) remains high. Some studies have identified prognostic factors capable of predicting ED, whereas no risk rating system for ED has been reported the literature. In this study, a classification was built to identify subgroup at high among patients with APL. Methods: Totally, 364 consecutive APL who received arsenic trioxide as induction therapy were included. Ten baseline clinical characteristics selected analysis, and they...
The pathogenesis of therapy-induced differentiation syndrome (DS) in patients with acute promyelocytic leukemia (APL) remains unclear. In this study, mRNA and microRNA (miRNA) expression profiling peripheral blood APL cells from complicated vs. without DS were integratively analyzed to explore the mechanisms underlying arsenic trioxide treatment-associated DS. By integrating differentially expressed data microRNAs their computationally predicted target genes, as well transcription factors...